Amgen Potential Autoimmune Drug Meets Primary Endpoint in Late-Stage Study

MT Newswires Live11-11

Amgen's (AMGN) potential Sjogren's disease treatment dazodalibep has met its primary endpoint of demonstrating statistically significant reductions in systemic disease activity compared with placebo in a late-stage trial, the company said Wednesday.

Sjogren's disease is a chronic autoimmune condition causing dry eyes and a dry mouth and potentially impacting other organs.

Both the 1,500 milligram every four-week and the 3,000 milligram every 12-week regiments of dazodalibep showed reductions in disease activity, the company said.

Patients treated with the drug showed greater increases in saliva flow, and oral dryness, compared with placebo, the company said.

Serious adverse events and discontinuations due to adverse events were "balanced" across three treatment groups, the company said.

Shares of the company were down more than 1% in recent Wednesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment